BY OUR PLATFORMS
BY THERAPEUTIC AREA
BY RESEARCH STAGE
20 April 2020
The Pharma company GB Science has got impressive results of their Cannabinoid formulation after testing them in Zebrafish Parkinson models.
The company states that it has selected the model because it addresses the underlying pathology of PD, rather than the genetic markers associated with PD, as they may be secondary rather than causal. Taking into account the results which show statistical relevance, it seems that this was indeed the correct decision!
The set-up used a neurotoxin to induce PD-like symptoms related to the loss of dopamine producing neurons, something that is directly related to the major symptoms of PD. As readout these neurons have been counted to see if in the group with the compounds neurons suffered less death (Also known as neuroprotection).
The experiment have been taken-out by the National Research Council of Canada (NRC), which stated that they believe the zebrafish model may be superior to the rodent models in this case, as the assay takes only a few weeks instead of a few months.
Even though the animal models are rather complementary than “substitutive”, at ZeClinics we share the thought that the Parkinson assays – as well as other efficacy assays - can be remarkably optimized by including zebrafish screening into the pipeline. This results have impact in several manners, as not only they show the effectiveness of the model, but also the effectiveness of Cannabis-related formulations “per sé” as well as their suitability with the model.
Quite impressive GBSiences, well done!
Your email address will not be published. Required fields are marked *
Save my name, email, and website in this browser for the next time I comment.